Statement: the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing an implant.
Primary_evidence: INTERVENTION 1:    Lapatinib With Paclitaxel   Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/meters squared (m^2) intravenously (IV) over the course of 3 hours, every 3 weeks. The treatment group was stratified by sites of metastatic disease and stage of disease. Participants were treated until disease progression, unacceptable toxicity, or consent withdrawal. INTERVENTION 2:    Placebo With Paclitaxel   Participants received matching placebo orally OD with paclitaxel (175 mg/m^2 IV) over the course of 3 hours, every 3 weeks. The treatment group was stratified by sites of metastatic disease and stage of disease. Participants were treated until disease progression, unacceptable toxicity, or consent withdrawal.
Secondary_evidence: INTERVENTION 1:    AlloDerm RTU   Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement. AlloDerm RTU INTERVENTION 2:    SurgiMend PRS   Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement. SurgiMend PRS